|
|
Other links at Articles > Business of Medicine |
| 3. |
Niacin Plus Laropiprant "Not Approvable" in US
|
|
|
The FDA has issued a "not-approvable" letter to Merck with regard to its new combination, which is being developed as a treatment to raise HDL cholesterol while reducing the flushing associated with niacin alone. However, the product has just received an approval recommendation in Europe. Heartwire
|
|
|